Utilization of Quantitative In Vivo Pharmacology Approaches to Assess Combination Effects of Everolimus and Irinotecan in Mouse Xenograft Models of Colorectal Cancer
Figure 2
Western blot analysis of everolimus and SN38 treatment effects in HCT8, HT29 and HCT116 cells.
Akt, p-Akt, PARP, cleaved PARP, total ribosomal S6 kinase (S6), ribosomal phospho-S6 kinase (pS6), ERK, p-ERK, p21 and α-tubulin were measured in all lines following 24 hours of treatment with RAD (20 nM), SN38 (4 nM) or the combination of the two. Molecular weights are presented next to protein name in parenthesis. Note that SN38 is used in in vitro assays instead of irinotecan since it is the active metabolite.